Home > Therapeutic area expertise > Neuroscience clinical trials

Central Nervous Systems (CNS) trials are inherently complex. Unlike many other therapeutic areas, neuroscience trials rely heavily on subjective endpoints and human judgment. Among the numerous challenges, endpoint subjectivity, the complexity and heterogeneity of patient populations, and data accuracy and variability are frequently cited.
To mitigate these challenges, designing effective Rater Training programs and combining them with flexible and user friendly eCOA solution is the only option to derisk your neuroscience clinical trials data and enhance the chances of clinical trials success.
At Kayentis, we have the experience and expertise to tackle the challenges of your CNS trials. Our partnership with RWS helps improve consistency across sites, strengthen endpoint reliability, and support inspection-ready datasets.
We have extensive experience across many indications, including Parkinson’s disease, Alzheimer’s disease, neuropathies, ataxia, and DMD, and with multiple scales, including C-SSRS, ADAS-Cog14, CDR-SB, and CDAS.
Guillaume Juge
CEO at Kayentis
“Capturing data digitally isn’t enough, sponsors need data they can trust. By aligning rater qualification with purpose-built eCOA workflows, we help reduce variability and give teams greater confidence in their results. This partnership with RWS brings a more coordinated approach, aligning how clinicians are trained, certified and monitored with how data is captured and controlled.”